This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer's Mad Dash: Regeneron to $400; Conn's a No-Touch

NEW YORK (TheStreet) -- On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, was very excited about Regeneron's (REGN - Get Report) new cholesterol drug, Alirocumab. 

The company's anti-cholesterol drug is an alternative to statin and reduces the risk of strokes. Regeneron is partnered with Sanofi (SNY - Get Report) for Alirocumab. 

The stock is breaking out, Cramer said, adding that Credit Suisse suggests it can go to $400 per share. 

"It's a very big win for Regeneron. It could be a multi-billion market," he said. 

Turning to Conn's (CONN - Get Report) , Cramer noted that the stock is plummeting -- down over 30%. Management expressed concern that customers would not be paying Conn's the money it is owed. 

Investors want exposure to domestic retailers to protect themselves from geopolitical risks, Cramer said, but not all domestic retailers are created equal. 

He concluded that he is not a buyer of Conn's following the selloff, because a lot of investors still want to get out of the stock. 

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CONN $13.34 2.90%
SNY $40.67 -1.20%
REGN $366.61 -1.30%
AAPL $94.42 -0.80%
FB $117.91 0.41%


Chart of I:DJI
DOW 17,712.42 -38.49 -0.22%
S&P 500 2,056.97 -6.40 -0.31%
NASDAQ 4,748.1640 -15.06 -0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs